Biogen traded at $212.58 this Tuesday July 5th, increasing $1.95 or 0.93 percent since the previous trading session. Looking back, over the last four weeks, Biogen gained 7.85 percent. Over the last 12 months, its price fell by 38.36 percent. Looking ahead, we forecast Biogen to be priced at 204.92 by the end of this quarter and at 188.71 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
212.58
Daily Change
0.93%
Yearly
-38.36%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 153.93 0.13 0.08% 33.01%
Acadia Pharmaceuticals 15.27 0.90 6.26% -36.72%
Acorda Therapeutics 0.49 0.01 1.66% -89.35%
ALKERMES 31.43 0.90 2.95% 22.97%
Amgen 246.73 1.18 0.48% 1.26%
Bayer 55.52 -1.72 -3.00% 9.55%
Biogen 212.58 1.95 0.93% -38.36%
Bluebird Bio 5.05 0.77 17.99% -83.73%
BioMarin Pharmaceutical 86.36 1.38 1.62% 2.12%
Bristol-Myers Squibb 75.96 -0.88 -1.15% 13.97%
Esperion Therapeutics 6.99 0.54 8.37% -64.80%
Gilead Sciences 62.34 -0.02 -0.03% -8.87%
Intercept Pharmaceuticals 15.15 1.02 7.22% -20.43%
Incyte Corp 79.25 1.58 2.03% -4.91%
Intra Cellular Therapies 57.09 1.92 3.48% 35.61%
Eli Lilly 327.18 2.47 0.76% 38.98%
Merck & Co 92.64 0.22 0.24% 18.60%
Moderna Inc 155.54 5.59 3.73% -33.34%
Marinus Pharmaceuticals 5.02 0.26 5.46% -73.21%
Neurocrine Biosciences 98.30 -0.95 -0.96% 0.87%
Novartis 80.91 -0.74 -0.91% -4.31%
Puma Biotechnology 2.66 -0.12 -4.32% -69.43%
Pfizer 51.64 -0.67 -1.28% 31.43%
PTC Therapeutics 43.78 1.93 4.61% 0.99%
Ultragenyx Pharmaceutical 63.80 1.15 1.84% -30.21%
Regeneron Pharmaceuticals 596.56 1.16 0.19% 2.46%
Sanofi 97.12 -1.22 -1.24% 11.93%
Seattle Genetics 176.77 -3.34 -1.85% 15.91%
Sangamo BioSciences 4.67 0.39 9.11% -58.49%
Sanofi 50.18 -0.83 -1.63% -2.43%
Sarepta Therapeutics 75.74 0.03 0.04% 3.43%
Teva Pharmaceutical Industries Ltd 2,746.00 0 0% -13.97%
United Therapeutics 237.15 -0.85 -0.36% 28.00%
Vertex Pharmaceuticals 288.98 1.66 0.58% 44.45%

Indexes Price Day Year
US500 3837 6.06 0.16% -11.66%
USND 11322 194.39 1.75% -22.79%
USNDX 11821 222.33 1.92% -20.05%

Biogen
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.